FDA Issues Nationwide Recall for Blood Pressure Medication Over Quality Failure

The U.S. Food and Drug Administration (FDA) has issued a nationwide recall for more than 3,700 bottles of prescription blood pressure medication after the pills failed to meet quality standards. The recall involves specific lots of a combination medication produced by New Jersey-based Macleods Pharma USA Inc.

Recall Details and Product Information

The recall, which was initiated by Macleods Pharma USA on Oct. 7, 2026, was classified by the FDA as a Class II recall on Oct. 26, 2026. According to the FDA, a Class II recall is a situation in which use of or exposure to a violative product "may cause temporary or medically reversible adverse health consequences" but the likelihood of serious health consequences is considered remote.

The affected medication is a combination of three active ingredients: Olmesartan Medoxomil (40 mg), Amlodipine (10 mg), and Hydrochlorothiazide (12.5 mg). These medications are used to treat hypertension, or high blood pressure, according to the Mayo Clinic.

According to an enforcement report and various news reports, the recall includes the following specific products:

In total, the recall covers 3,528 30-count bottles and 216 90-count bottles, totaling 3,744 bottles.

Reason for the Recall

The FDA cited "failed dissolution specifications" as the reason for the recall. Dissolution testing is used to examine whether a medicine releases its active ingredients at the required rate under specified testing conditions. The failure indicates that the pills did not dissolve as required during testing.

According to reports from USA TODAY and IBTimes UK, this failure raises concerns regarding the medication's effectiveness, as the tablets may not release their ingredients at the proper rate, potentially preventing the medicine from lowering blood pressure as expected.

Guidance for Consumers

Patients are advised to check their medicine cabinets for the specific lot numbers and National Drug Codes (NDC) listed above. The FDA notes that the recall affects products distributed nationwide, so the location where a prescription was filled does not rule out a match.

Regarding the use of the medication, the FDA's consumer guidance states that patients can generally continue taking medicines subject to Class II recalls unless the recalling company or the FDA directs otherwise. The agency advises, "In some instances, stopping your medicine may be more harmful to your health than continuing to take the recalled medicine."

Medical professionals recommend that patients who find a matching lot number contact their pharmacist or healthcare provider to discuss the recall and obtain guidance on a replacement. Patients should not stop taking prescribed blood pressure medication without medical advice.

Why it matters

This recall follows a similar incident in September, when India-based Inventia Healthcare Ltd. recalled 13,567 bottles of 25-milligram chlorthalidone tablets after they also failed dissolution testing. Chlorthalidone is used to treat high blood pressure and fluid retention, according to the Mayo Clinic.

---

Sources

• nbcchicago.com: Thousands of bottles of blood pressure medication recalled by FDA – NBC Chicago
• foxbusiness.com: Blood pressure medicine recall: Thousands of bottles pulled nationwide | Fox Business
• journalarta.com: FDA Recalls Macleods Blood Pressure Tablets After Quality Test Failure — JournalArta Global
• economictimes.indiatimes.com: Blood pressure drug recall: FDA flags thousands of bottles after pills fail quality tests; here's what to check - The Economic Times
• ibtimes.co.uk: US FDA Flags Nationwide Recall of Over 3,700 Blood Pressure Medication Bottles Over Effectiveness Concerns | IBTimes UK
• fox13seattle.com: Thousands of blood pressure medication bottles recalled nationwide after pills fail quality test | FOX 13 Seattle

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.